Drug Trial Radar · NCT03222843
Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient
Last checked: Nov 19, 2026Latest source record: Aug 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
424
Actual
Start
Jun 30, 2017
Primary completion
Nov 11, 2019
Study completion Jan 7, 2021
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with chronic, previously treated ITP. Dosage could be adjusted (2.5\~.75 mg/day) to maintain platelet counts 50\~250×109/L
Conditions
- Idiopathic Thrombocytopenic Purpura
Interventions
Hetrombopag OlamineDrug
once daily
matching placeboDrug
once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- the proportion of patients with a platelet count ≥50×109/L after Day 57.Time frame: Baseline to Week 8
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Union Hospital Tongji Medical College Huazhong University of Science and technology
Wuhan, Hubei, China
West China Hospital,Sichuan University
Chengdu, Sichuan, China
Hospital of Blood Diseases, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.